Polymorphic oxidation of debrisoquine in women with breast cancer.

Abstract

Oxidative polymorphism of debrisoquine (DBQ) was determined in 98 women with breast cancer (mean age 59.2 years, SD 10.7; 18 were premenopausal when diagnosed), and in 446 healthy control women (mean age 25.4 years, SD 9.15). All of them were free of drug interactions with oxidation of DBQ. Ten patients (10.2%), all of them postmenopausal when diagnosed… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.